Principal
Investigator: Richard Rosen, MD
Enrollment
Status: Open Enrollment
Objective:
To evaluate the efficacy of intravitreal bevasiranib sodium as maintenance therapy for Age-Related Macular Degeneration following initiation of anti-VEGF therapy with 3 doses of Lucentis®
Eligibility:
Contact
Information: Jenny Gallardo, CRC (212)-614-8386; Katy Tai, CR Manager (212) 979-4251
|